Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Exits Boehringer Ingelheim Distribution Deal Early

This article was originally published in The Pink Sheet Daily

Executive Summary

Termination of the agreement to distribute Mobic, Flomax and Micardis in the U.S. is expected to boost Abbott’s gross margins, the company reports.

You may also be interested in...

Abbott Manufacturing Cuts Will Make Up For Lower Mobic Profits

Consolidation and staff reductions in global manufacturing operations are designed to improve gross margins, which have been negatively impacted by sales of lower margin products, such as Mobic and Flomax, which Abbott distributes under a deal with Boehringer. Abbott is cutting 700 manufacturing positions.

Abbott Flomax Reps Will Shift To Smaller Products Once Co-Promotion Deal Ends

The company will move from actively co-promoting to merely distributing Flomax at the end of August under its 1999 agreement with Boehringer Ingelheim. Tarka and Omnicef could pick up reps from the Flomax sales force, Abbott says.

J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business

The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts